Associated tags: Patient, Hospital, Therapy, CGT, Pharmaceutical industry, Fausto Pocar, Security (finance)
Locations: UNITED STATES, EUROPE, ASIA, NORTH AMERICA, CALIFORNIA, MIDDLE EAST, NEW YORK, MASSACHUSETTS, BELGIUM, WALLONIA, WHITE PLAINS, NY, US
GERMANTOWN, Md., April 15, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the year ended December 31, 2023.
Key Points:
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) in order to improve access and outcomes in healthcare, today provided a business update for the year ended December 31, 2023.
- “Orgenesis is a company that has set as its goal to make cell and gene therapies available and affordable.
- Although there has been widespread acceptance of the field with multiple approvals of new products, the lack of funding has hit early-stage development companies the hardest.
- We believe that we are now on more solid financial footing having already received collaboration payments in excess of $6 million.
Retrieved on:
Wednesday, April 10, 2024
The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
Key Points:
- The collaboration’s goal is to transform the production of cell and gene therapies, making these vital treatments more affordable and accessible to patients worldwide.
- By combining Germfree’s expertise in designing, manufacturing, and maintaining advanced manufacturing facility environments with Orgenesis’ cutting-edge processes and analytical development capabilities, the partnership seeks to significantly reduce the production costs of cell and gene therapy products.
- Vered Caplan, CEO of Orgenesis, stated, “Under the agreement, Orgenesis and Germfree will join forces to co-market Orgenesis’ decentralized Octomera service platform, and its Octomera Mobile Processing Units and Labs (OMPULs™) globally.
- This partnership is expected to foster innovation, particularly in how we approach and execute cell and gene therapy manufacturing.
GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe.
Key Points:
- GERMANTOWN, Md., March 18, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralizing cell and gene therapies (CGTs), today announced that its CEO, Vered Caplan, will be presenting at the upcoming Bioprocessing Summit Europe.
- Ms. Caplan is scheduled to present on Tuesday, March 19th, at 2:10 PM CET.
- Bioprocessing Summit Europe brings together 750+ upstream, downstream, bioproduction, analytical and formulation professionals.
- This 3-day, 12-track meeting has quickly become a premier meeting in the European bioprocessing calendar and is regarded by many as “the fastest growing bioprocessing meeting in Europe” following record growth in 2023.
Retrieved on:
Wednesday, March 13, 2024
Exosome,
Quality control,
ULB,
B cell,
Public,
Adipose tissue,
Cell,
EVS,
Partnership,
Patient,
CMMI,
GMP,
MSC,
Ulcer,
Pharmaceutical industry Consortium members include: Orgenesis, Cilyx, CMMI, convExYO, EXO Biologics, ExoXpert, Genflow Biosciences, LiveDrop, ULB, UMONS and Xomexbio.
Key Points:
- Consortium members include: Orgenesis, Cilyx, CMMI, convExYO, EXO Biologics, ExoXpert, Genflow Biosciences, LiveDrop, ULB, UMONS and Xomexbio.
- This grant is the second such project awarded to an Orgenesis consortium by the Walloon Government partnership, ATMP-Partenariat d’Innovation Technologique (ATMP-PIT), in collaboration with BioWin, the health cluster of Wallonia, and the Public service of Wallonia.
- EXOFASTTRACK is a collaborative project focused on accelerating the development of multiple therapeutic exosomes for rapid clinical evaluation.
- Therapeutic exosomes are based on very large-scale reproduction, several billion copies, of an intercellular message specific to the producing cells, e.g.
The warrants are exercisable immediately and expire five years from the date of issuance.
Key Points:
- The warrants are exercisable immediately and expire five years from the date of issuance.
- The Company expects to receive gross proceeds of approximately $2.3 million before deducting related offering expenses.
- The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.
- The securities to be sold in this private placement will not be registered under the Securities Act of 1933, as amended, or any state securities laws, and will be sold pursuant to Regulation D of the Securities Act.
Retrieved on:
Thursday, February 29, 2024
AI,
Research,
TRAIL,
Marche-en-Famenne,
Database,
Learning,
Cell,
Public service,
Université catholique de Louvain,
Partnership,
Medical device GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM).
Key Points:
- GERMANTOWN, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Orgenesis Inc. (Nasdaq:ORGS) (“Orgenesis” or the “Company”), a global leader in decentralized cell and gene therapies (CGTs), today announced that the Company’s consortium was awarded a €2.0 million grant from the Walloon Government in Belgium, titled: “Monitoring with AI of Decentralized ATMP Manufacturing” (MAIDAM).
- The consortium members include: Orgenesis Services Belgium, Université catholique de Louvain (UCLouvain) / TRusted AI Labs (TRAIL) and DNAlytics.
- The MAIDAM project is focused on developing AI-based approaches for the monitoring and improvement of decentralized manufacturing processes for ATMPs via federated machine and reinforcement learning utilizing cell therapy processing on small and standardized manufacturing units.
- This project brings together a top-notch consortium with very complementary expertise in manufacturing of cell therapies, AI, and digitization of biomanufacturing processes.
Retrieved on:
Wednesday, January 31, 2024
Calendar,
Pressure,
Metalmark Capital,
Therapy,
Public,
Patient,
Safety,
FDA,
Biotechnology,
Acquisition,
GMP,
Hospital,
Fine chemical These factors highlight the need and are driving demand for our decentralized cell therapy approach.
Key Points:
- These factors highlight the need and are driving demand for our decentralized cell therapy approach.
- In parallel to progressing our decentralized Octomera platform, the Company’s most advanced oncology therapeutic in development continues to make significant advances in terms of decentralized GMP production and proof of concept with respect to efficacy and safety.
- We are very appreciative of Metalmark for supporting us through the biotech winter and seeing our decentralized vision for the future.
- To learn more, please visit our website .
Retrieved on:
Tuesday, November 14, 2023
(NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it ranked 171 on the Deloitte Technology Fast 500 ™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
Key Points:
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced it ranked 171 on the Deloitte Technology Fast 500 ™, a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 29th year.
- Vered Caplan, CEO of Orgenesis, commented, “We are very proud to be recognized on the prestigious 2023 Deloitte Technology Fast 500™ list.
- “While software and services and life sciences continue to dominate the top 10, we are encouraged to see other categories making their mark.
- “Over the nearly 30 years we’ve been compiling the Technology Fast 500, we’ve seen new categories emerge, growth rates explode, and certain regional markets shine from the bright talent they attract.
Retrieved on:
Monday, November 13, 2023
Regenerative medicine,
Research,
Security (finance),
Government,
CIRM,
Patient,
Marketing,
Partnership,
Hospital,
UC,
CGT,
Pharmaceutical industry (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023.
Key Points:
- (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the third quarter ended September 30, 2023.
- It is important to note that the Company deconsolidated Octomera on June 30, 2023, though the Company still holds a 75% stake in the business.
- Accordingly, the results of Octomera’s operations subsequent to June 30, 2023, are not reflected in the Company’s consolidated financial statements.
- Octomera itself recognized revenue of $2.7 million, reflecting a temporary delay in cell processing and cell process development contracts, which are expected to be completed in the fourth quarter of 2023 and first quarter of 2024.
Retrieved on:
Wednesday, November 8, 2023
Titan,
Sale,
Peer-to-peer file sharing,
Security (finance),
Telephone,
Form,
Bangladesh Securities and Exchange Commission,
Warrant,
CVC Capital Partners,
Prospectus,
CGT,
S-3 The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $0.78.
Key Points:
- The combined effective purchase price for each share of common stock and associated warrant to purchase one share of common stock will be $0.78.
- Under the terms of the securities purchase agreement, Orgenesis has agreed to issue 1,410,256 shares of common stock and warrants to purchase up to an aggregate of 1,410,256 shares of common stock (the “Warrants”).
- Titan Partners Group, a division of American Capital Partners, is acting as sole placement agent for the offering.
- The offering is expected to close on or about November 9, 2023, subject to the satisfaction of customary closing conditions.
